Skip to content
OpenCapital
Get started

Beam Therapeutics BEAM Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
——
Biogen logo
BiogenBIIB
——
Incyte logo
IncyteINCY
——

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$3.42B+24.5%

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%—
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%—
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beam Therapeutics's contingent consideration fair value adjustments?
Beam Therapeutics (BEAM) reported contingent consideration fair value adjustments of -$514K in Q1 2026.
How has Beam Therapeutics's contingent consideration fair value adjustments changed year-over-year?
Beam Therapeutics's contingent consideration fair value adjustments decreased by 2003.7% year-over-year, from $27K to -$514K.
What is the long-term trend for Beam Therapeutics's contingent consideration fair value adjustments?
Over 2 years (2022 to 2024), Beam Therapeutics's contingent consideration fair value adjustments has grown at a -70.7% compound annual growth rate (CAGR), from -$18.9M to -$1.62M.